KellyNGodbyMD
Oncology • Birmingham, ALAssociate Professor, Medicine, University of Alabama School of Medicine
Dr. Godby is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
619 19th St S
Birmingham, AL 35249Phone+1 205-934-5038
Education & Training
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011- University of Alabama Medical CenterResidency, Internal Medicine, 2005 - 2008
Mercer University School of MedicineClass of 2005
Certifications & Licensure
AL State Medical License 2007 - 2024- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy Start of enrollment: 2011 Jul 01
Publications & Presentations
PubMed
- 5 citationsDaratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.Natalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, Kelly N Godby, Jacob Laubach
Blood Cancer Journal. 2024-04-22 - 215 citationsRecent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States.Luciano J. Costa, Ilene Brill, James L. Omel, Kelly N. Godby, Shaji Kumar
Blood Advances. 2017-01-10 - 64 citationsEvaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.Smith Giri, Alyssa Grimshaw, Susan Bal, Kelly N. Godby, Prakash Kharel
JAMA Oncology. 2020-11-01
Journal Articles
- Second Primary Malignancy After Multiple Myeloma‐Population Trends and Cause‐Specific MortalityParameswaran Hari, Luciano J Costa, Saurabh Chhabra, Kelly N Godby, British Journal of Haematology
Abstracts/Posters
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Kelly N. Godby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Di...Kelly N. Godby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Kelly N. Godby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
